Biotech

All Articles

Lilly articles much more favorable data on its every week the hormone insulin prospect

.On the heels of an FDA being rejected for its main rival Novo Nordisk, Eli Lilly is pushing on in t...

IN 8bio halts phase 2 test, lays off fifty percent of labor force

.Only a couple of months after application the 1st client in a phase 2 test for recently detected gl...

Lilly, Haya ink $1B biobuck excessive weight pact to browse darker genome

.Eli Lilly's search for being overweight aim ats has actually led it to the dark genome. The Big Pha...

ArsenalBio increases $325M, rotates out of former lead resource

.Arsenal Biosciences is actually proceeding up. The tissue therapy business has actually added $325 ...

Lilly- supported weight management biotech reports IPO

.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually sub...

Aelis' cannabis use drug flunks phase 2b, driving Indivior to reassess $100M option

.Aelis Farma's chances of protecting an easy, beneficial selection on a $100 million possibility pay...

ProKidney stops period 3 test not required for cell therapy confirmation

.ProKidney has actually ceased among a pair of phase 3 trials for its own tissue therapy for kidney ...

Vaxcyte climbs on 'impressive' 31-valent PCV gain against Pfizer

.Vaxcyte revealed what analysts named "magnificent" period 1/2 information for its 31-valent pneumoc...

Recursion's mind condition trial reveals little evidence of effectiveness

.Recursion has stumbled with an early exam of its own tech-enabled technique to drug discovery, stat...

Acepodia, Pfizer click on with each other for chemistry-based cell therapy

.Contact it a situation of really good chemistry: Acepodia, a biotech based upon Nobel Prize-winning...